Related Experiment Videos
Insights
Unlicensed and off-label prescribing in children is prevalent due to research challenges and lack of industry incentives. Addressing paediatric drug safety requires better trials and drug delivery considerations.
Area of Science:
- Pediatric Pharmacology
- Drug Safety in Children
- Clinical Trial Design
Background:
- Unlicensed and off-label medication use is common in pediatric populations, spanning neonates to adolescents.
- Challenges in pediatric clinical trials and limited financial incentives for the pharmaceutical industry contribute to this issue.
- Drug handling and efficacy vary significantly across pediatric age groups, complicating extrapolation from adult data.
Discussion:
- Recent cases of adrenal failure linked to inhaled corticosteroids highlight issues in pediatric prescribing.
- Factors contributing to adverse events include assuming adult disease equivalence, inadequate pediatric diagnostic tools, and poor drug delivery methods.
- Despite some progress, significant improvements are needed in pediatric drug safety and prescribing practices.
Key Insights:
- Pediatric drug prescribing faces significant hurdles, including research difficulties and economic disincentives.
- Adverse events like adrenal failure underscore critical gaps in understanding drug behavior in children.
- Effective pediatric pharmacotherapy requires tailored approaches, not just adult data extrapolation.
Outlook:
- Further research and regulatory changes are essential to improve pediatric drug safety.
- Incentivizing the pharmaceutical industry could drive crucial pediatric drug development.
- A concerted effort is needed to ensure safe and effective medication use for all children.
Abstract:
Unlicensed and off-label prescribing is common in children. This is likely to be due to a combination of the difficulty in carrying out reliable clinical trials in children and the lack of financial reward for the industry. The term 'paediatric' encompasses preterm babies to near adult-sized adolescents, and all aspects of drug handling differ over this age range, making extrapolation very problematic. Recently, adrenal failure with inhaled corticosteroid use in children has been highlighted. Examination reveals that this is due to a combination of factors common in paediatric prescribing; including the assumption that adult diseases are the same as paediatric diseases, the lack of good diagnostic tools in small children and lack of thought about problems of drug delivery. Although some steps are being taken to improve paediatric prescribing, much more needs to be done. One approach may be to offer incentives to the pharmaceutical industry. The present state of affairs is unsatisfactory and cannot be allowed to continue.